Molecule News and Research

RSS

Selvita commences IND-enabling studies for its first oncology drug candidate

Selvita, the largest drug discovery company in Central and Eastern Europe, announced today that it is commencing IND-enabling studies for SEL24 project, the company’s first oncology drug candidate.

1 Apr 2015

NIH awards $2.1 million grant to counter antibiotic resistance in Gram-negative bacteria

The National Institutes of Health has awarded Dr. Walter Fast, associate professor of medicinal chemistry at The University of Texas at Austin's College of Pharmacy, a four-year $2.1 million grant to develop small-molecules that counter antibiotic resistance in Gram-negative bacteria. If successful, the research could lead to new drugs for treating bacterial infections that are resistant to most antibiotics.

1 Apr 2015

FGF21 protein can boost regenerative effects of human PPARα

Researchers at UC Davis have illuminated an important distinction between mice and humans: how human livers heal. The difference centers on a protein called PPARα, which activates liver regeneration. Normally, mouse PPARα is far more active and efficient than the human form, allowing mice to quickly regenerate damaged livers.

1 Apr 2015

New study sheds light on natural small molecule with antimicrobial effects

Scientists from the Florida campus of The Scripps Research Institute have uncovered the unique mechanism of a powerful natural product with wide-ranging antifungal, antibacterial, anti-malaria and anti-cancer effects.

31 Mar 2015

Study provides insights into basis for cognitive dysfunction

Scientists at Columbia University's Mailman School of Public Health have identified a unique pattern of immune molecules in the cerebrospinal fluid of people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) that provides insights into the basis for cognitive dysfunction--frequently described by patients as "brain fog"--as well as new hope for improvements in diagnosis and treatment.

31 Mar 2015

Researchers identify potential drug molecule that kills cancer cells

The average living cell needs communication skills: It must transmit a constant stream of messages quickly and efficiently from its outer walls to the inner nucleus, where most of the day-to-day decisions are made.

31 Mar 2015

New drug shows potential against rare type of acute leukemia

Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well.

30 Mar 2015

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Phase II/III psoriasis trial for the Company's drug candidate CF101 did not achieve its primary endpoint.

30 Mar 2015

DURECT initiates DUR-928 multi-dose Phase 1 clinical trial for NAFLD, NASH and AKI

DURECT Corporation today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program.

30 Mar 2015

One round of adenosine triphosphate turnover sufficient for SNARE complex disassembly

In 2013, James E. Rothman, Randy W. Schekman, and Thomas C. Südhof won the Nobel Prize in Physiology or Medicine for their discoveries of molecular machineries for vesicle trafficking, a major transport system in cells for maintaining cellular processes. Vesicle traffic acts as a kind of "home-delivery service" in cells.

30 Mar 2015

Fujifilm enters into definitive agreement to acquire Cellular Dynamics International

FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) and Cellular Dynamics International, Inc. (CEO: Robert J. Palay), a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, today announced that the two companies have entered into a definitive agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger.

30 Mar 2015

MRI technique may help detect cancerous cells

Imaging tests like mammograms or CT scans can detect tumors, but figuring out whether a growth is or isn't cancer usually requires a biopsy to study cells directly. Now results of a Johns Hopkins study suggest that MRI could one day make biopsies more effective or even replace them altogether by noninvasively detecting telltale sugar molecules shed by the outer membranes of cancerous cells.

30 Mar 2015

Stopping cellular quality-control mechanism can make chemotherapy more effective

A University of Rochester team found a way to make chemotherapy more effective, by stopping a cellular quality-control mechanism, according to a study published today in Nature Communications.

27 Mar 2015

Lycera achieves milestone in Merck research collaboration

Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease, today announced the achievement of a milestone under the Company's collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment.

25 Mar 2015

New study reveals how cells sort out loops meant to encode microRNAs

Just as two DNA strands naturally arrange themselves into a helix, DNA's molecular cousin RNA can form hairpin-like loops. But unlike DNA, which has a single job, RNA can play many parts -- including acting as a precursor for small molecules that block the activity of genes. These small RNA molecules must be trimmed from long hairpin-loop structures, raising a question: How do cells know which RNA loops need to be processed this way and which don't?

25 Mar 2015

New imaging technique could give precise information about structures inside tissues, cells

One infrared scan can give pathologists a window into the structures and molecules inside tissues and cells, enabling fast and broad diagnostic assessments, thanks to an imaging technique developed by University of Illinois researchers and clinical partners.

25 Mar 2015

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher Pharmaceuticals Inc. today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma for moderate to severe plaque psoriasis and rheumatoid arthritis.

23 Mar 2015

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.

23 Mar 2015

Saccharin could potentially lead to development of drugs for difficult-to-treat cancers

Saccharin, the artificial sweetener that is the main ingredient in Sweet 'N Low, Sweet Twin and Necta, could do far more than just keep our waistlines trim. According to new research, this popular sugar substitute could potentially lead to the development of drugs capable of combating aggressive, difficult-to-treat cancers with fewer side effects.

23 Mar 2015

Scientists use optical radiation to treat cancer at the cellular level

Wanting to achieve early cancer detection, a group of scientists from the Center for Research in Optics (CIO) of Guadalajara, in Mexico, seeks to address the problem from the cell with optical radiation.

23 Mar 2015

Molecule News and Research

Selvita commences IND-enabling studies for its first oncology drug candidate

NIH awards $2.1 million grant to counter antibiotic resistance in Gram-negative bacteria

FGF21 protein can boost regenerative effects of human PPARα

New study sheds light on natural small molecule with antimicrobial effects

Study provides insights into basis for cognitive dysfunction

Researchers identify potential drug molecule that kills cancer cells

New drug shows potential against rare type of acute leukemia

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

DURECT initiates DUR-928 multi-dose Phase 1 clinical trial for NAFLD, NASH and AKI

One round of adenosine triphosphate turnover sufficient for SNARE complex disassembly

Fujifilm enters into definitive agreement to acquire Cellular Dynamics International

MRI technique may help detect cancerous cells

Stopping cellular quality-control mechanism can make chemotherapy more effective

Lycera achieves milestone in Merck research collaboration

New study reveals how cells sort out loops meant to encode microRNAs

New imaging technique could give precise information about structures inside tissues, cells

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Saccharin could potentially lead to development of drugs for difficult-to-treat cancers

Scientists use optical radiation to treat cancer at the cellular level

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News